Supraventricular Tachycardia
Conditions
Keywords
Tachycardia, Supraventricular, Anti-Arrhythmia Agents, Arrhythmias, Cardiac
Brief summary
The infants diagnosed with SVT are treated with antiarrhythmic medication to prevent the recurrence of SVT. This prospective observational cohort study evaluates efficacy and safety of shortening duration of antiarrhythmic medication to four months in infants with SVT. Primary outcome is incidence of recurrent SVT in infants after 4 months of antiarrhythmic medication compared to retrospectively reviewed cohort.
Interventions
DRUGPropranolol
3 mg/kg/d, divided in four doses when age less than 3 months and in three doses when age more than 3 months
DRUGFlecainide
80 mg/m2/d
DRUGAmiodarone
Single dose of 10 mg/kg/d 10-14 days, 5 mg/kg/d
Sponsors
Helsinki University Central Hospital
Kuopio University Hospital
Oulu University Hospital
Turku University Hospital
Tampere University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 6 Months
Healthy volunteers
No
Inclusion criteria
* Age 6 months or less * Documented SVT due to AVRT or AVNRT
Exclusion criteria
* Age \> 6 months * Ectopic atrial tachycardia * Atrial flutter * Atrial fibrillation * Permanent junctional reciprocating tachycardia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence of SVT after antiarrhythmic medication | 1 year follow-up |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of participants with treatment failure | 4 months of antiarrhythmic medication |
| Prevalence of adverse events | 4 months of antiarrhythmic medication |
| Recurrence of SVT after one year follow-up | 5 year |
Countries
Finland
Outcome results
None listed